{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T04:13:51Z","timestamp":1795061631197,"version":"4.10.2"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jpsychires.2022.04.037","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T23:32:46Z","timestamp":1653435166000},"page":"693-709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":193,"special_numbering":"C","title":["Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review &amp; meta-analysis"],"prefix":"10.1016","volume":"151","author":[{"given":"Yazen","family":"Alnefeesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chen-Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5197-2227","authenticated-orcid":false,"given":"Ella","family":"Krane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Youshay","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson B.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Ceban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Di Vincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7010-1785","authenticated-orcid":false,"given":"Shakila","family":"Meshkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9629-4493","authenticated-orcid":false,"given":"Roger C.M.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartej","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yena","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-2191","authenticated-orcid":false,"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jpsychires.2022.04.037_bib1","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.biopsych.2017.01.002","article-title":"What's the buzz about hydroxynorketamine? Is it the history, the story, the debate, or the promise?","volume":"81","author":"Abdallah","year":"2017","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.neubiorev.2021.09.020","article-title":"Trace amine-associated receptor 1 (TAAR1): potential application in mood disorders: a systematic review","volume":"131","author":"Alnefeesi","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3389\/fpsyt.2020.00844","article-title":"The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication","volume":"11","author":"Andrashko","year":"2020","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib4","first-page":"113","article-title":"Effects of intranasal (S)-ketamine on veterans with co-morbid treatment-resistant depression and PTSD: a retrospective case series","volume":"46","author":"Artin","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.jpsychires.2022.04.037_bib5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4103\/0253-7613.161277","article-title":"Ketamine-induced affective switch in a patient with treatment-resistant depression","volume":"47","author":"Banwari","year":"2015","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jpsychires.2021.09.018","article-title":"Repurposed drugs as adjunctive treatments for mania and bipolar depression: a meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials","volume":"143","author":"Bartoli","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2015.10.034","article-title":"BDNF \u2014 a key transducer of antidepressant effects","volume":"102","author":"Bj\u00f6rkholm","year":"2016","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.jpsychires.2022.04.037_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res. Synth. Methods"},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I 2 is not an absolute measure of heterogeneity: I 2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res. Synth. Methods"},{"issue":"8","key":"10.1016\/j.jpsychires.2022.04.037_bib10","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1017\/S1461145708009309","article-title":"A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression","volume":"11","author":"Brunoni","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.jpsychires.2022.04.037_bib12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00406-021-01264-w","article-title":"Effects of treatment refractoriness and brain-derived neurotrophic factor Val66Met polymorphism on antidepressant response to low-dose ketamine infusion","volume":"271","author":"Chen","year":"2021","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib13","first-page":"2441","article-title":"Conditional BDNF delivery from astrocytes rescues memory deficits, spine density and synaptic properties in the 5xFAD mouse model of Alzheimer disease","volume":"39","author":"de Pins","year":"2019","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.jpsychires.2022.04.037_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Contr. Clin. Trials"},{"key":"10.1016\/j.jpsychires.2022.04.037_bib15","doi-asserted-by":"crossref","first-page":"114321","DOI":"10.1016\/j.psychres.2021.114321","article-title":"Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: results from the canadian rapid treatment center of excellence","volume":"307","author":"Di Vincenzo","year":"2022","journal-title":"Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tins.2011.11.004","article-title":"Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents","volume":"35","author":"Duman","year":"2012","journal-title":"Trends Neurosci."},{"issue":"8","key":"10.1016\/j.jpsychires.2022.04.037_bib17","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41386-020-0663-6","article-title":"Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression","volume":"45","author":"Farmer","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1073\/pnas.1814709116","article-title":"Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2 R ,6 R)-hydroxynorketamine","volume":"116","author":"Fukumoto","year":"2019","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"4","key":"10.1016\/j.jpsychires.2022.04.037_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/0269881118760660","article-title":"Repeated intranasal ketamine for treatment-resistant depression \u2013 the way to go? Results from a pilot randomised controlled trial","volume":"32","author":"G\u00e1lvez","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-020-0727-8","article-title":"The influence of ketamine's repeated treatment on brain topology does not suggest an antidepressant efficacy","volume":"10","author":"Gass","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.12740\/PP\/20566","article-title":"Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy","volume":"48","author":"Gosek","year":"2014","journal-title":"Psychiatr. Pol."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jpsychires.2019.08.005","article-title":"Ketamine metabolite pilot study in a suicidal depression trial","volume":"117","author":"Grunebaum","year":"2019","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib23","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41398-018-0311-7","article-title":"Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression","volume":"8","author":"Guo","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jpsychires.2022.04.037_bib24","author":"Hashimoto"},{"issue":"2","key":"10.1016\/j.jpsychires.2022.04.037_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/1673-5374.177708","article-title":"Practical application of the neuroregenerative properties of ketamine: real world treatment experience","volume":"11","author":"Henderson","year":"2016","journal-title":"Neural Regeneration Res."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib26","article-title":"Longitudinal CSF proteome profiling in mice to uncover the acute and sustained mechanisms of action of rapid acting antidepressant (2R,6R)-hydroxynorketamine (HNK)","volume":"13","author":"Herzog","year":"2021","journal-title":"Neurobiol. Stress."},{"issue":"7","key":"10.1016\/j.jpsychires.2022.04.037_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jpsychires.2022.04.037_bib28","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jad.2018.09.037","article-title":"Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: a randomized, double blind, placebo controlled trial","volume":"243","author":"Ionescu","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113645","article-title":"Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression","volume":"296","author":"Kang","year":"2021","journal-title":"Psychiatr. Res."},{"issue":"11","key":"10.1016\/j.jpsychires.2022.04.037_bib31","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1176\/appi.ajp.2012.12040531","article-title":"Synaptic mechanisms underlying rapid antidepressant action of ketamine","volume":"169","author":"Kavalali","year":"2012","journal-title":"Am. J. Psychiatr."},{"issue":"11","key":"10.1016\/j.jpsychires.2022.04.037_bib32","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.biopsych.2012.05.031","article-title":"Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients","volume":"72","author":"Laje","year":"2012","journal-title":"Biol. Psychiatr."},{"issue":"12","key":"10.1016\/j.jpsychires.2022.04.037_bib33","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biol. Psychiatr."},{"issue":"3","key":"10.1016\/j.jpsychires.2022.04.037_bib34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.jpsychires.2022.04.037_bib35","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/0269881120978398","article-title":"Repeated subcutaneous esketamine for treatment-resistant depression: impact of the degree of treatment resistance and anxiety comorbidity","volume":"35","author":"Lucchese","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.jpsychires.2022.04.037_bib36","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/sim.698","article-title":"A comparison of methods to detect publication bias in meta-analysis","volume":"20","author":"Macaskill","year":"2001","journal-title":"Stat. Med."},{"issue":"4","key":"10.1016\/j.jpsychires.2022.04.037_bib37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1017\/S0033291714001603","article-title":"A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes","volume":"45","author":"McGirr","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib38","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","article-title":"The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis","volume":"276","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jpsychires.2022.04.037_bib39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jpsychires.2021.11.036","article-title":"Pharmacogenomics of ketamine: a systematic review","volume":"145","author":"Meshkat","year":"2022","journal-title":"J. Psychiatr. Res."},{"issue":"7","key":"10.1016\/j.jpsychires.2022.04.037_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"2","key":"10.1016\/j.jpsychires.2022.04.037_bib43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evidence Based Med."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib44","year":"2022"},{"key":"10.1016\/j.jpsychires.2022.04.037_bib45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jad.2021.06.032","article-title":"Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: a systematic review","volume":"293","author":"Ng","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib46","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jad.2021.12.134","article-title":"Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis","volume":"302","author":"Nu\u00f1ez","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib47","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"n71","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jpsychires.2022.04.037_bib48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4103\/psychiatry.IndianJPsychiatry_345_17","article-title":"A possible role for ketamine in suicide prevention in emergency and mainstream psychiatry","volume":"59","author":"Sathyanarayana Rao","year":"2017","journal-title":"Indian J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib49","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.2147\/NDT.S273287","article-title":"Metabolic risk factors and cardiovascular safety in ketamine use for treatment resistant depression","volume":"16","author":"Szarmach","year":"2020","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"3","key":"10.1016\/j.jpsychires.2022.04.037_bib50","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF02294384","article-title":"A general linear model for estimating effect size in the presence of publication bias","volume":"60","author":"Vevea","year":"1995","journal-title":"Psychometrika"},{"key":"10.1016\/j.jpsychires.2022.04.037_bib51","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3389\/fpsyt.2020.00516","article-title":"Affective switch associated with oral, low dose ketamine treatment in a patient with treatment resistant bipolar I depression. Case report and literature review","volume":"11","author":"Wilkowska","year":"2020","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib52","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2147\/NDT.S325000","article-title":"Intravenous ketamine infusions in treatment-resistant bipolar depression: an open-label naturalistic observational study","volume":"17","author":"Wilkowska","year":"2021","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"4","key":"10.1016\/j.jpsychires.2022.04.037_bib53","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol. Psychiatr."},{"issue":"3","key":"10.1016\/j.jpsychires.2022.04.037_bib54","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite Pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"issue":"7604","key":"10.1016\/j.jpsychires.2022.04.037_bib55","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jpsychires.2022.04.037_bib56","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.biopsych.2012.03.004","article-title":"Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression","volume":"72","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib57","doi-asserted-by":"crossref","first-page":"e01674","DOI":"10.1002\/brb3.1674","article-title":"Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression\u2014an open-label three-week pilot study","volume":"10","author":"Zhuo","year":"2020","journal-title":"Brain. Behave."},{"issue":"2","key":"10.1016\/j.jpsychires.2022.04.037_bib58","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"Aan het Rot","year":"2010","journal-title":"Biol. Psychiatr."},{"issue":"4","key":"10.1016\/j.jpsychires.2022.04.037_bib59","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/JCP.0000000000000717","article-title":"Oral ketamine in treatment-resistant depression","volume":"37","author":"Al Shirawi","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.jpsychires.2022.04.037_bib60","first-page":"S152","article-title":"Serial IV ketamine infusions are effective for the treatment of comorbid post-traumatic stress disorder and treatment-resistant major depression","volume":"41","author":"Albott","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.jpsychires.2022.04.037_bib61","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/0269216320910351","article-title":"Repeated subcutaneous esketamine administration for depressive symptoms and pain relief in a terminally ill cancer patient: a case report","volume":"34","author":"Barbosa","year":"2020","journal-title":"Palliat. Med."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2020.01.002","article-title":"Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients","volume":"123","author":"Basso","year":"2020","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib63","first-page":"1","article-title":"Combined transcranial magnetic stimulation and ketamine for treatment of refractory mood disorder, anxiety, and pain: a case report","volume":"8","author":"Best","year":"2017","journal-title":"Curr. Neurobiol."},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib64","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40810-015-0003-y","article-title":"Combined ketamine and transcranial magnetic stimulation for treatment resistant depression in the context of chronic OCD: a case report","volume":"1","author":"Best","year":"2015","journal-title":"Neuropsychioatric. Electrophysiol."},{"issue":"3","key":"10.1016\/j.jpsychires.2022.04.037_bib65","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/00207454.2014.933834","article-title":"Combination therapy utilizing ketamine and transcranial magnetic stimulation for treatment-resistant depression: a case report","volume":"125","author":"Best","year":"2015","journal-title":"Int. J. Neurosci."},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib66","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13256-015-0520-0","article-title":"Ketamine and transcranial magnetic stimulation treatment for bipolar II disorder: a case report","volume":"9","author":"Best","year":"2015","journal-title":"J. Med. Case Rep."},{"issue":"Suppl. 1","key":"10.1016\/j.jpsychires.2022.04.037_bib67","first-page":"S294","article-title":"Ketamine for treatment-refractory obsessive-compulsive disorder","volume":"36","author":"Bloch","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.jpsychires.2022.04.037_bib68","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.biopsych.2012.05.028","article-title":"Effects of ketamine in treatment-refractory obsessive-compulsive disorder","volume":"72","author":"Bloch","year":"2012","journal-title":"Biol. Psychiatr."},{"issue":"Suppl. 1","key":"10.1016\/j.jpsychires.2022.04.037_bib69","first-page":"S168","article-title":"Continuation phase intravenous ketamine in adults with treatment-resistant depression","volume":"41","author":"Bobo","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.jpsychires.2022.04.037_bib70","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/JCP.0000000000001006","article-title":"Effects of repeated intravenous ketamine in treatment-resistant geriatric depression: a case series","volume":"39","author":"Bryant","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.jpsychires.2022.04.037_bib71","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/1039856214545547","article-title":"Dosing and effectiveness of ketamine anesthesia for electroconvulsive therapy (ECT): a case series","volume":"22","author":"Bryson","year":"2014","journal-title":"Australas. Psychiatr."},{"issue":"Suppl. 6","key":"10.1016\/j.jpsychires.2022.04.037_bib72","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1016\/j.euroneuro.2019.09.339","article-title":"P.319 Intravenous ketamine long-term use in two bipolar depression cases: 1-year follow-up","volume":"29","author":"Bustillo","year":"2019","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"4","key":"10.1016\/j.jpsychires.2022.04.037_bib73","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/PRA.0000000000000316","article-title":"Is ketamine the future clozapine for depression? A case series and literature review on maintenance ketamine in treatment-resistant depression with suicidal behavior","volume":"24","author":"Chan","year":"2018","journal-title":"J. Psychiatr. Pract."},{"issue":"7","key":"10.1016\/j.jpsychires.2022.04.037_bib74","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.biopsych.2012.03.029","article-title":"Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression","volume":"72","author":"Cornwell","year":"2012","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib75","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2147\/NDT.S135623","article-title":"Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review","volume":"13","author":"Correia-Melo","year":"2017","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib76","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1526-4637.2006.00101.x","article-title":"Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions","volume":"7","author":"Correll","year":"2006","journal-title":"Pain Med."},{"issue":"Suppl. 2","key":"10.1016\/j.jpsychires.2022.04.037_bib77","first-page":"S526","article-title":"Preliminary investigation of EEG predictors in an open-label, flexible-dose, repeated infusions of ketamine as augmentation in treatment resistant depression","volume":"38","author":"Cusin","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib78","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/0004867416631828","article-title":"Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step intravenous dose escalation","volume":"51","author":"Cusin","year":"2017","journal-title":"Aust. N. Z. J. Psychiatr."},{"issue":"6","key":"10.1016\/j.jpsychires.2022.04.037_bib79","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0269881114527361","article-title":"Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic","volume":"28","author":"Diamond","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.jpsychires.2022.04.037_bib80","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4088\/JCP.09m05327blu","article-title":"Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder","volume":"71","author":"DiazGranados","year":"2010","journal-title":"J. Clin. Psychiatr."},{"issue":"2","key":"10.1016\/j.jpsychires.2022.04.037_bib81","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","article-title":"Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy","volume":"51","author":"Dore","year":"2019","journal-title":"J. Psychoact. Drugs"},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib82","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jad.2012.05.042","article-title":"Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder","volume":"145","author":"Duncan","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib83","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.npbr.2020.02.008","article-title":"Safety and efficacy of esketamine nasal spray in a depressed patient who was being treated with tranylcypromine: a case report","volume":"36","author":"Dunner","year":"2020","journal-title":"Neurol. Psychiatr. Brain Res."},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12904-019-0499-1","article-title":"A rapid positive influence of S-ketamine on the anxiety of patients in palliative care: a retrospective pilot study","volume":"19","author":"Falk","year":"2020","journal-title":"BMC Palliat. Care"},{"issue":"Suppl. 1","key":"10.1016\/j.jpsychires.2022.04.037_bib85","first-page":"S159","article-title":"Efficacy and safety of intravenous low-dose ketamine for depression in an academic clinical practice","volume":"41","author":"Feifel","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl. 1","key":"10.1016\/j.jpsychires.2022.04.037_bib86","first-page":"S173","article-title":"Long-term treatment of depression with repeated intramuscular ketamine","volume":"43","author":"Feifel","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.jpsychires.2022.04.037_bib87","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4103\/0019-5545.111461","article-title":"Intramuscular ketamine in acute depression: a report on two cases","volume":"55","author":"Harihar","year":"2013","journal-title":"Indian J. Psychiatr."},{"issue":"Suppl. 1","key":"10.1016\/j.jpsychires.2022.04.037_bib88","first-page":"429","article-title":"Ketamine improves negative attitudes toward self in treatment-resistant depression","volume":"44","author":"Hasler","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.jpsychires.2022.04.037_bib89","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/WNF.0000000000000104","article-title":"Augmentation therapy with serial intravenous ketamine over 18 months in a patient with treatment resistant depression","volume":"38","author":"Hassamal","year":"2015","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.jpsychires.2022.04.037_bib90","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/1673-5374.177708","article-title":"Practical application of the neuroregenerative properties of ketamine: real world treatment experience","volume":"11","author":"Henderson","year":"2016","journal-title":"Neural Regeneration Res."},{"issue":"9","key":"10.1016\/j.jpsychires.2022.04.037_bib91","doi-asserted-by":"crossref","first-page":"e932","DOI":"10.4088\/JCP.14m09049","article-title":"Effect of baseline anxious depression on initial and sustained antidepressant response to Ketamine","volume":"75","author":"Ionescu","year":"2014","journal-title":"J. Clin. Psychiatr."},{"issue":"7","key":"10.1016\/j.jpsychires.2022.04.037_bib92","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/jpm.2010.9808","article-title":"Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care","volume":"13","author":"Irwin","year":"2010","journal-title":"J. Palliat. Med."},{"issue":"5","key":"10.1016\/j.jpsychires.2022.04.037_bib93","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00702-015-1500-7","article-title":"Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression","volume":"123","author":"Kallmunzer","year":"2016","journal-title":"J. Neural. Transm."},{"issue":"4","key":"10.1016\/j.jpsychires.2022.04.037_bib94","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/jcpt.12669","article-title":"Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up","volume":"43","author":"Kwon","year":"2018","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib95","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","article-title":"Intravenous arketamine for treatment-resistant depression: open-label pilot study","volume":"271","author":"Leal","year":"2020","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"issue":"15\u201316","key":"10.1016\/j.jpsychires.2022.04.037_bib96","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4414\/smw.2007.11852","article-title":"Intravenous ketamine therapy in a patient with a treatment-resistant major depression","volume":"137","author":"Liebrenz","year":"2007","journal-title":"Swiss Med. Wkly."},{"issue":"4 PART 2","key":"10.1016\/j.jpsychires.2022.04.037_bib97","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1080\/15622970701420481","article-title":"Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression","volume":"10","author":"Liebrenz","year":"2009","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2020.03.048","article-title":"Baseline insomnia as a predictor of antidepressant efficacy to repeated intravenous ketamine for unipolar and bipolar depression: a preliminary study","volume":"271","author":"Liu","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"4","key":"10.1016\/j.jpsychires.2022.04.037_bib99","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/2045125316675578","article-title":"Use of repeated intravenous ketamine therapy in treatment-resistant bipolar depression with suicidal behaviour: a case report from Spain","volume":"7","author":"Lopez-Diaz","year":"2017","journal-title":"Therapeutic. Adv. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib100","first-page":"262","article-title":"Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: a case series","author":"Lu","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"12","key":"10.1016\/j.jpsychires.2022.04.037_bib101","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.4088\/JCP.08m04659","article-title":"Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist","volume":"70","author":"Machado-Vieira","year":"2009","journal-title":"J. Clin. Psychiatr."},{"issue":"9 Suppl. 3","key":"10.1016\/j.jpsychires.2022.04.037_bib102","first-page":"S542","article-title":"Ketamine therapy and its efficacy in treatment of depression","volume":"61","author":"Mandal","year":"2019","journal-title":"Indian J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib103","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bdi.12941","article-title":"The effectiveness of ketamine on anxiety, irritability, and agitation: implications for treating mixed features in adults with major depressive or bipolar disorder","volume":"22","author":"McIntyre","year":"2020","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib40","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jad.2020.05.088","article-title":"The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: results from the Canadian Rapid Treatment Center of Excellence","volume":"274","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"12","key":"10.1016\/j.jpsychires.2022.04.037_bib104","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11920-017-0855-x","article-title":"Use of ketamine in elderly patients with treatment-resistant depression","volume":"19","author":"Medeiros da Frota Ribeiro","year":"2017","journal-title":"Curr. Psychiatr. Rep."},{"issue":"4","key":"10.1016\/j.jpsychires.2022.04.037_bib105","first-page":"48","article-title":"Maintenance ketamine treatment produces long-term recovery from depression","volume":"17","author":"Messer","year":"2010","journal-title":"Prim. Psychiatr."},{"issue":"1\u20132","key":"10.1016\/j.jpsychires.2022.04.037_bib106","first-page":"56","article-title":"Ketamine therapy for treatment-resistant depression in a patient with multiple sclerosis: a case report","volume":"14","author":"Messer","year":"2017","journal-title":"Innovation Clinic. Neurosci."},{"issue":"4","key":"10.1016\/j.jpsychires.2022.04.037_bib107","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol. Psychiatr."},{"issue":"Suppl. 4","key":"10.1016\/j.jpsychires.2022.04.037_bib108","doi-asserted-by":"crossref","first-page":"S866","DOI":"10.1016\/S0924-977X(17)31554-7","article-title":"Safety and efficacy of ketamine infusion in treatment-resistant depression with multiple medical comorbidities: a case report","volume":"27","author":"Nakahira","year":"2017","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"7","key":"10.1016\/j.jpsychires.2022.04.037_bib109","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/0269881113486718","article-title":"Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder","volume":"27","author":"Niciu","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"Suppl. 4","key":"10.1016\/j.jpsychires.2022.04.037_bib110","doi-asserted-by":"crossref","first-page":"S854","DOI":"10.1016\/S0924-977X(17)31534-1","article-title":"Intravenous ketamine for depression and congruent psychotic symptomatology: description of two consecutive cases","volume":"27","author":"Olazabal","year":"2017","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib111","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1055\/s-0029-1237375","article-title":"Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series","volume":"43","author":"Paslakis","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpsychires.2022.04.037_bib112","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jad.2016.10.026","article-title":"Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion","volume":"208","author":"Pennybaker","year":"2017","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.jpsychires.2022.04.037_bib113","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.biopsych.2008.09.029","article-title":"Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist","volume":"65","author":"Phelps","year":"2009","journal-title":"Biol. Psychiatr."},{"issue":"5","key":"10.1016\/j.jpsychires.2022.04.037_bib114","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0269881113478283","article-title":"Serial infusions of low-dose ketamine for major depression","volume":"27","author":"Rasmussen","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.jpsychires.2022.04.037_bib115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.brs.2017.01.433","article-title":"Ketamine infusions after failure to respond to electroconvulsive therapy: a case series report","volume":"10","author":"Riva-Posse","year":"2017","journal-title":"Brain Stimul."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib116","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jad.2020.07.089","article-title":"Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: a retrospective chart review","volume":"276","author":"Sakurai","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib117","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/appy.12220","article-title":"Treatment of suicidal depression with ketamine in rapid cycling bipolar disorder","volume":"8","author":"Sampath","year":"2016","journal-title":"Asia Pac. Psychiatr."},{"issue":"12","key":"10.1016\/j.jpsychires.2022.04.037_bib118","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1176\/appi.ajp.2019.18101219","article-title":"Treatment-resistant depression and ketamine response in a patient with bilateral amygdala damage","volume":"176","author":"Scheele","year":"2019","journal-title":"Am. J. Psychiatr."},{"issue":"9","key":"10.1016\/j.jpsychires.2022.04.037_bib119","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jcph.122","article-title":"Repeated S-ketamine infusions in therapy resistant depression: a case series","volume":"53","author":"Segmiller","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib120","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jad.2013.10.036","article-title":"Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression","volume":"155","author":"Shiroma","year":"2014","journal-title":"J. Affect. Disord."},{"issue":"9","key":"10.1016\/j.jpsychires.2022.04.037_bib121","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1089\/jpm.2008.9828","article-title":"Intravenous ketamine \u201cburst\u201d for refractory depression in a patient with advanced cancer","volume":"11","author":"Stefanczyk-Sapieha","year":"2008","journal-title":"J. Palliat. Med."},{"issue":"4","key":"10.1016\/j.jpsychires.2022.04.037_bib122","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.psym.2013.12.002","article-title":"Beneficial pre-ECT ketamine infusion in a patient with treatment-resistant depression","volume":"55","author":"Sultan","year":"2014","journal-title":"Psychosomatics"},{"issue":"1\u20133","key":"10.1016\/j.jpsychires.2022.04.037_bib123","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jad.2012.10.015","article-title":"A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression","volume":"147","author":"Szymkowicz","year":"2013","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.jpsychires.2022.04.037_bib124","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J. Clin. Psychiatr."},{"issue":"1","key":"10.1016\/j.jpsychires.2022.04.037_bib125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/jcpt.13041","article-title":"Repeated ketamine injections in synergy with antidepressants for treating refractory depression: a case showing 6-month improvement","volume":"45","author":"Wang","year":"2020","journal-title":"J. Clin. Pharm. Therapeut."},{"issue":"4","key":"10.1016\/j.jpsychires.2022.04.037_bib126","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11731","article-title":"Acute and longer-term outcomes using ketamine as a clinical treatment at the yale psychiatric hospital","volume":"79","author":"Wilkinson","year":"2018","journal-title":"J. Clin. Psychiatr."},{"issue":"3","key":"10.1016\/j.jpsychires.2022.04.037_bib127","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000457960","article-title":"Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression","volume":"86","author":"Wilkinson","year":"2017","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib128","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3389\/fpsyt.2020.00516","article-title":"Affective switch associated with oral, low dose ketamine treatment in a patient with treatment resistant bipolar I depression. Case report and literature review","volume":"11","author":"Wilkowska","year":"2020","journal-title":"Front. Psychiatr."},{"issue":"Suppl. 1","key":"10.1016\/j.jpsychires.2022.04.037_bib129","first-page":"236A","article-title":"Naltrexone plus ketamine for the treatmentofmajor depressive disorder and alcohol use disorder","volume":"42","author":"Yoon","year":"2018","journal-title":"Alcohol Clin. Exp. Res."},{"issue":"4","key":"10.1016\/j.jpsychires.2022.04.037_bib130","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1089\/jpm.2011.0314","article-title":"Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer","volume":"15","author":"Zanicotti","year":"2012","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.112907","article-title":"Ketamine plus propofol-electroconvulsive therapy (ECT) transiently improves the antidepressant effects and the associated brain functional alterations in patients with propofol-ECT-resistant depression","volume":"287","author":"Zhang","year":"2020","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib132","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jad.2020.06.020","article-title":"A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression","volume":"275","author":"Zheng","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2022.04.037_bib133","doi-asserted-by":"crossref","first-page":"e01674","DOI":"10.1002\/brb3.1674","article-title":"Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression\u2014an open-label three-week pilot study","volume":"10","author":"Zhuo","year":"2020","journal-title":"Brain. Behave."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395622002400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395622002400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:37:26Z","timestamp":1758368246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395622002400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":132,"alternative-id":["S0022395622002400"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2022.04.037","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2022.04.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}